The wider picture
The BA.3.2 variant, commonly referred to as the Cicada variant, has emerged as a notable descendant of the BA.3 omicron subvariant that first appeared in 2022. Identified in South Africa in November 2024, this variant has quickly spread to over 20 countries, including 25 states in the United States. As health authorities monitor its rise, understanding the symptoms associated with this variant becomes increasingly important.
One of the most striking features of the Cicada variant is its extensive genetic makeup, carrying approximately 70 to 75 mutations in its spike protein. This significant number of mutations has raised questions about the variant’s transmissibility and severity. However, current evidence suggests that BA.3.2 does not lead to more severe illness compared to earlier variants. Dr. Adolfo García-Sastre, a prominent figure in infectious disease research, stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.”
Common symptoms associated with the Cicada variant include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. These symptoms largely mirror those seen in previous COVID-19 strains, particularly the Omicron variants. Health experts emphasize that most cases remain mild to moderate, resembling flu-like illness, especially among vaccinated individuals. As one health expert noted, “Most cases remain mild and can be managed at home with rest and hydration.”
Despite the variant’s mutations, vaccines are expected to provide strong protection against severe disease, even if breakthrough infections occur. Health authorities continue to advocate for staying up to date with vaccinations and taking precautions in crowded settings, particularly as the variant spreads in densely populated areas. Observers are encouraged to remain vigilant as the situation evolves.
As the Cicada variant gains traction, health experts are closely monitoring its impact. Symptoms linked to this variant remain consistent with those of previous strains, with no new or unusual signs reported thus far. This consistency in symptoms may help in early identification and management of cases, which is crucial for controlling the spread of the variant.
However, there are concerns regarding the effectiveness of current COVID-19 vaccines against the Cicada variant due to its multiple mutations. While vaccines are still expected to provide a level of protection, some experts warn that their effectiveness may not be as robust as against earlier strains. This has led to renewed discussions about the importance of booster shots and ongoing vaccination efforts.
In summary, the emergence of the Cicada variant underscores the need for continued vigilance in the fight against COVID-19. With its rapid spread and familiar symptom profile, the public is urged to remain informed and proactive in protecting their health. As health authorities work to monitor and respond to this variant, the emphasis on vaccination and preventive measures remains critical.
